Pneumo23
Systemic-Onset Juvenile Idiopathic Arthritis
Institut National de la Santé Et de la Recherche Médicale, FranceUNKNOWNPhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Systemic-Onset Juvenile Idiopathic Arthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION) Novartis Pharmaceuticals | Phase 3 | BB |
Anakinra Institut National de la Santé Et de la Recherche Médicale, France | Phase 2/3 | B |
Hydroxyurea Paul Szabolcs | Phase 2 | CCC |
Melphalan Paul Szabolcs | Phase 2 | CCC |
Fludarabine Paul Szabolcs | Phase 2 | CCC |
Alemtuzumab Paul Szabolcs | Phase 2 | CCC |
Thiotepa Paul Szabolcs | Phase 2 | CCC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →